The approval was based on data from a late-stage study showing the
drug along with chemotherapy improved event-free survival and
pathologic complete response compared to chemotherapy alone in
patients with resectable non-small cell lung cancer, the drugmaker
said.
Non-small cell lung cancer is the most common form of lung cancer,
accounting for about 85% of the estimated 2.2 million new cases of
lung cancer diagnosed each year worldwide, according to the World
Health Organization.
Opdivo, Bristol's flagship cancer drug that was first approved in
2014, brought in $1.99 billion in sales during company's last
reported quarter.
![](http://archives.lincolndailynews.com/2022/Mar/05/images/ads/current/charrons_bch_2022.png)
[to top of second column] |
![](http://archives.lincolndailynews.com/2022/Mar/05/images/ads/current/2021_lda_Businessdirectory.png) The drug is used in use in
patients with several types of cancer including
bladder, lung, blood, head and neck and advanced
melanoma. It belongs to a class of drugs
designed to help the body's immune system fight
cancer by blocking a protein called Programmed
cell death protein 1 (PD-1).
(Reporting by Mrinalika Roy in Bengaluru;
Editing by Amy Caren Daniel)
[© 2022 Thomson Reuters. All rights
reserved.] This material may not be published,
broadcast, rewritten or redistributed.
Thompson Reuters is solely responsible for this content. |